miR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function

Cancer Letters

Volumn 380, Issue 1, 2016, Pages 257-262

  Noman, Muhammad Zaeem ^a   Janji, Bassam ^b   Berchem, Guy ^b   Chouaib, Salem ^a  

^a INSERM   (France)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

HIF; Hypoxia; Immunosuppression and antitumor immune response; miR 210; MVs; Tumor microenvironment

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN;

CANCER CELL; CELL INTERACTION; CELL MEDIATED CYTOTOXICITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EXOSOME; HUMAN; HYPOXIA; HYPOXIC MICROVESICLE; IMMUNOREGULATION; KILLER CELL; MEMBRANE MICROPARTICLE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR HYPOXIA;

ANIMALS; CELL COMMUNICATION; CELL-DERIVED MICROPARTICLES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT;

EID: 84948845576     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.10.026     Document Type: Review

References (65)

1. [1] Noman, M.Z., Messai, Y., Carre, T., Akalay, I., Meron, M., Janji, B., et al. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit. Rev. Immunol 31 (2011), 357–377.
2. [2] Harris, A.L., Hypoxia – a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002), 38–47.
3. [3] Semenza, G.L., Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci 33 (2012), 207–214.
4. [4] Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
5. [5] Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., Noman, M.Z., Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol, 3, 2012, 21.
6. [6] Facciabene, A., Peng, X., Hagemann, I.S., Balint, K., Barchetti, A., Wang, L.P., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475 (2011), 226–230.
7. [7] Hasmim, M., Noman, M.Z., Messai, Y., Bordereaux, D., Gros, G., Baud, V., et al. Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-beta1. J. Immunol 191 (2013), 5802–5806.
8. [8] Noman, M.Z., Chouaib, S., Targeting hypoxia at the forefront of anticancer immune responses. Oncoimmunology, 3, 2014, e954463.
9. [9] Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med 211 (2014), 781–790.
10. [10] Keith, B., Simon, M.C., Hypoxia-inducible factors, stem cells, and cancer. Cell 129 (2007), 465–472.
11. [11] Semenza, G.L., Hypoxia-inducible factors in physiology and medicine. Cell 148 (2012), 399–408.
12. [12] Wightman, B., Ha, I., Ruvkun, G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75 (1993), 855–862.
13. [13] Vasudevan, S., Tong, Y., Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation. Science 318 (2007), 1931–1934.
14. [14] Orom, U.A., Nielsen, F.C., Lund, A.H., MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 30 (2008), 460–471.
15. [15] Place, R.F., Li, L.C., Pookot, D., Noonan, E.J., Dahiya, R., MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 1608–1613.
16. [16] Fayyad-Kazan, H., Rouas, R., Fayyad-Kazan, M., Badran, R., El Zein, N., Lewalle, P., et al. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J. Biol. Chem 287 (2012), 9910–9922.
17. [17] Alvarez-Garcia, I., Miska, E.A., MicroRNA functions in animal development and human disease. Development 132 (2005), 4653–4662.
18. [18] Kulshreshtha, R., Davuluri, R.V., Calin, G.A., Ivan, M., A microRNA component of the hypoxic response. Cell Death Differ 15 (2008), 667–671.
19. [19] Kulshreshtha, R., Ferracin, M., Wojcik, S.E., Garzon, R., Alder, H., Agosto-Perez, F.J., et al. A microRNA signature of hypoxia. Mol. Cell. Biol 27 (2007), 1859–1867.
20. [20] Loscalzo, J., The cellular response to hypoxia: tuning the system with microRNAs. J. Clin. Invest 120 (2010), 3815–3817.
21. [21] Bruning, U., Cerone, L., Neufeld, Z., Fitzpatrick, S.F., Cheong, A., Scholz, C.C., et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol. Cell. Biol 31 (2011), 4087–4096.
22. [22] Devlin, C., Greco, S., Martelli, F., Ivan, M., miR-210: more than a silent player in hypoxia. IUBMB Life 63 (2011), 94–100.
23. [23] Huang, X., Ding, L., Bennewith, K.L., Tong, R.T., Welford, S.M., Ang, K.K., et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell 35 (2009), 856–867.
24. [24] Huang, X., Le, Q.T., Giaccia, A.J., MiR-210 – micromanager of the hypoxia pathway. Trends Mol. Med 16 (2010), 230–237.
25. [25] Camps, C., Buffa, F.M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res 14 (2008), 1340–1348.
26. [26] Noman, M.Z., Buart, S., Romero, P., Ketari, S., Janji, B., Mari, B., et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 72 (2012), 4629–4641.
27. [27] Fasanaro, P., Alessandra, Y.D., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem 283 (2008), 15878–15883.
28. [28] Bodempudi, V., Hergert, P., Smith, K., Xia, H., Herrera, J., Peterson, M., et al. miR-210 promotes IPF fibroblast proliferation in response to hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol 307 (2014), L283–L294.
29. [29] Qi, J., Qiao, Y., Wang, P., Li, S., Zhao, W., Gao, C., microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett 586 (2012), 1201–1207.
30. [30] Wang, H., Flach, H., Onizawa, M., Wei, L., McManus, M.T., Weiss, A., Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat. Immunol 15 (2014), 393–401.
31. [31] Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., Lotvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol 9 (2007), 654–659.
32. [32] Al-Nedawi, K., Meehan, B., Micallef, J., Lhotak, V., May, L., Guha, A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol 10 (2008), 619–624.
33. [33] Balaj, L., Lessard, R., Dai, L., Cho, Y.J., Pomeroy, S.L., Breakefield, X.O., et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun, 2, 2011, 180.
34. [34] Record, M., Carayon, K., Poirot, M., Silvente-Poirot, S., Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim. Biophys. Acta 1841 (2014), 108–120.
35. [35] Christianson, H.C., Svensson, K.J., van Kuppevelt, T.H., Li, J.P., Belting, M., Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 17380–17385.
36. [36] Kucharzewska, P., Belting, M., Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J. Extracell. Vesicles, 2, 2013.
37. [37] Svensson, K.J., Kucharzewska, P., Christianson, H.C., Skold, S., Lofstedt, T., Johansson, M.C., et al. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 13147–13152.
38. [38] Gross, J.C., Chaudhary, V., Bartscherer, K., Boutros, M., Active Wnt proteins are secreted on exosomes. Nat. Cell Biol 14 (2012), 1036–1045.
39. [39] Thery, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol 9 (2009), 581–593.
40. [40] Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med 18 (2012), 883–891.
41. [41] Martinez-Lorenzo, M.J., Anel, A., Alava, M.A., Pineiro, A., Naval, J., Lasierra, P., et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp. Cell Res 295 (2004), 315–329.
42. [42] Clayton, A., Mitchell, J.P., Court, J., Linnane, S., Mason, M.D., Tabi, Z., Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol 180 (2008), 7249–7258.
43. [43] Kucharzewska, P., Christianson, H.C., Welch, J.E., Svensson, K.J., Fredlund, E., Ringner, M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 7312–7317.
44. [44] Ramteke, A., Ting, H., Agarwal, C., Mateen, S., Somasagara, R., Hussain, A., et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol. Carcinog 54 (2015), 554–565.
45. [45] Umezu, T., Tadokoro, H., Azuma, K., Yoshizawa, S., Ohyashiki, K., Ohyashiki, J.H., Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 124 (2014), 3748–3757.
46. [46] Aga, M., Bentz, G.L., Raffa, S., Torrisi, M.R., Kondo, S., Wakisaka, N., et al. Exosomal HIF1alpha supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene 33 (2014), 4613–4622.
47. [47] Admyre, C., Johansson, S.M., Qazi, K.R., Filen, J.J., Lahesmaa, R., Norman, M., et al. Exosomes with immune modulatory features are present in human breast milk. J. Immunol 179 (2007), 1969–1978.
48. [48] Hedlund, M., Nagaeva, O., Kargl, D., Baranov, V., Mincheva-Nilsson, L., Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS ONE, 6, 2011, e16899.
49. [49] Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med 7 (2001), 297–303.
50. [50] Andre, F., Chaput, N., Schartz, N.E., Flament, C., Aubert, N., Bernard, J., et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol 172 (2004), 2126–2136.
51. [51] Munich, S., Sobo-Vujanovic, A., Buchser, W.J., Beer-Stolz, D., Vujanovic, N.L., Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1 (2012), 1074–1083.
52. [52] Viaud, S., Terme, M., Flament, C., Taieb, J., Andre, F., Novault, S., et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE, 4, 2009, e4942.
53. [53] Simhadri, V.R., Reiners, K.S., Hansen, H.P., Topolar, D., Simhadri, V.L., Nohroudi, K., et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE, 3, 2008, e3377.
54. [54] Lugini, L., Cecchetti, S., Huber, V., Luciani, F., Macchia, G., Spadaro, F., et al. Immune surveillance properties of human NK cell-derived exosomes. J. Immunol 189 (2012), 2833–2842.
55. [55] Lv, L.H., Wan, Y.L., Lin, Y., Zhang, W., Yang, M., Li, G.L., et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J. Biol. Chem 287 (2012), 15874–15885.
56. [56] Pogge von Strandmann, E., Simhadri, V.R., von Tresckow, B., Sasse, S., Reiners, K.S., Hansen, H.P., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27 (2007), 965–974.
57. [57] Zech, D., Rana, S., Buchler, M.W., Zoller, M., Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun. Signal, 10, 2012, 37.
58. [58] Clayton, A., Tabi, Z., Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol. Dis 34 (2005), 206–213.
59. [59] Ashiru, O., Boutet, P., Fernandez-Messina, L., Aguera-Gonzalez, S., Skepper, J.N., Vales-Gomez, M., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 70 (2010), 481–489.
60. [60] Clayton, A., Mitchell, J.P., Court, J., Mason, M.D., Tabi, Z., Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67 (2007), 7458–7466.
61. [61] Liu, C., Yu, S., Zinn, K., Wang, J., Zhang, L., Jia, Y., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol 176 (2006), 1375–1385.
62. [62] Szczepanski, M.J., Szajnik, M., Welsh, A., Whiteside, T.L., Boyiadzis, M., Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 96 (2011), 1302–1309.
63. [63] Wang, T., Gilkes, D.M., Takano, N., Xiang, L., Luo, W., Bishop, C.J., et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E3234–E3242.
64. [64] Berchem, G., Noman, M.Z., Bosseler, M., Paggetti, J., Baconnais, S., Lecam, E., et al. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a transfer. OncoImmunology, 2015 in press.
65. [65] Sullivan, R.P., Leong, J.W., Fehniger, T.A., MicroRNA regulation of natural killer cells. Front. Immunol, 4, 2013, 44.